Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.

Sigmon SC, Dunn KE, Saulsgiver K, Patrick ME, Badger GJ, Heil SH, Brooklyn JR, Higgins ST.

JAMA Psychiatry. 2013 Dec;70(12):1347-54. doi: 10.1001/jamapsychiatry.2013.2216.

2.

Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.

Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG.

JAMA Intern Med. 2014 Dec;174(12):1947-54. doi: 10.1001/jamainternmed.2014.5302.

PMID:
25330017
3.

Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W.

Arch Gen Psychiatry. 2011 Dec;68(12):1238-46. doi: 10.1001/archgenpsychiatry.2011.121. Epub 2011 Nov 7.

4.

Characterizing opioid withdrawal during double-blind buprenorphine detoxification.

Dunn KE, Saulsgiver KA, Miller ME, Nuzzo PA, Sigmon SC.

Drug Alcohol Depend. 2015 Jun 1;151:47-55. doi: 10.1016/j.drugalcdep.2015.02.033. Epub 2015 Mar 12.

5.

Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.

Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ; PRO-814 Study Group.

JAMA. 2016 Jul 19;316(3):282-90. doi: 10.1001/jama.2016.9382.

PMID:
27434441
6.

Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.

Sigmon SC, Dunn KE, Badger GJ, Heil SH, Higgins ST.

Addict Behav. 2009 Mar;34(3):304-11. doi: 10.1016/j.addbeh.2008.11.017. Epub 2008 Nov 24.

7.

Spontaneous reductions in smoking during double-blind buprenorphine detoxification.

Patrick ME, Dunn KE, Badger GJ, Heil SH, Higgins ST, Sigmon SC.

Addict Behav. 2014 Sep;39(9):1353-6. doi: 10.1016/j.addbeh.2014.04.023. Epub 2014 May 5.

8.

Buprenorphine tapering schedule and illicit opioid use.

Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R.

Addiction. 2009 Feb;104(2):256-65. doi: 10.1111/j.1360-0443.2008.02455.x.

9.

The multi-site prescription opioid addiction treatment study: 18-month outcomes.

Potter JS, Dreifuss JA, Marino EN, Provost SE, Dodd DR, Rice LS, Fitzmaurice GM, Griffin ML, Weiss RD.

J Subst Abuse Treat. 2015 Jan;48(1):62-9. doi: 10.1016/j.jsat.2014.07.009. Epub 2014 Aug 2.

10.

A comparison of buprenorphine taper outcomes between prescription opioid and heroin users.

Nielsen S, Hillhouse M, Thomas C, Hasson A, Ling W.

J Addict Med. 2013 Jan-Feb;7(1):33-8. doi: 10.1097/ADM.0b013e318277e92e.

11.

Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers.

Meyer AC, Miller ME, Sigmon SC.

Addict Behav. 2015 Mar;42:189-93. doi: 10.1016/j.addbeh.2014.11.006. Epub 2014 Nov 18.

12.

Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.

Webster L, Hjelmström P, Sumner M, Gunderson EW.

J Addict Dis. 2016 Oct-Dec;35(4):325-338. Epub 2016 Jun 7.

PMID:
27267785
13.

Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.

Mokri A, Chawarski MC, Taherinakhost H, Schottenfeld RS.

Addiction. 2016 May;111(5):874-82. doi: 10.1111/add.13259. Epub 2016 Jan 26.

PMID:
26639678
14.

Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.

Woodcock EA, Lundahl LH, Greenwald MK.

Drug Alcohol Depend. 2015 Jan 1;146:89-96. doi: 10.1016/j.drugalcdep.2014.11.016. Epub 2014 Nov 26.

15.

Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.

Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, Brooklyn J.

Arch Gen Psychiatry. 2005 Oct;62(10):1157-64.

PMID:
16203961
16.

Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.

Gonzalez G, DiGirolamo G, Romero-Gonzalez M, Smelson D, Ziedonis D, Kolodziej M.

Drug Alcohol Depend. 2015 Nov 1;156:243-53. doi: 10.1016/j.drugalcdep.2015.09.020. Epub 2015 Sep 30.

17.

Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.

Mooney LJ, Nielsen S, Saxon A, Hillhouse M, Thomas C, Hasson A, Stablein D, McCormack J, Lindblad R, Ling W.

Contemp Clin Trials. 2013 Mar;34(2):196-204. doi: 10.1016/j.cct.2012.11.002. Epub 2012 Nov 16.

18.

Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.

Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, Patkar A, Chavoustie S, Blasey C, Sigmon S, Beebe KL.

Addiction. 2013 Dec;108(12):2141-9. doi: 10.1111/add.12315. Epub 2013 Sep 18.

19.

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

Gerra G, Fantoma A, Zaimovic A.

J Psychopharmacol. 2006 Nov;20(6):806-14. Epub 2006 Jan 9.

PMID:
16401652
20.

Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.

Dunn KE, Tompkins DA, Bigelow GE, Strain EC.

JAMA Psychiatry. 2017 Jul 12. doi: 10.1001/jamapsychiatry.2017.1838. [Epub ahead of print]

PMID:
28700791

Supplemental Content

Support Center